These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 4846402)

  • 21. Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.
    Benz C; Tillis T; Tattelman E; Cadman E
    Cancer Res; 1982 May; 42(5):2081-6. PubMed ID: 6175406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of advanced breast cancer with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP)].
    Rabinovich MG; Leone BA; Landó O
    Medicina (B Aires); 1981; 41(1):65-70. PubMed ID: 7266359
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents.
    Glass A; Wieand HS; Fisher B; Redmond C; Lerner H; Wolter J; Shibata H; Plotkin D; Foster R; Margolese R; Wolmark N
    Cancer Treat Rep; 1981; 65(5-6):363-76. PubMed ID: 7016322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
    Hill GJ; Grage TB; Wilson W; Ansfield FJ
    J Surg Oncol; 1972; 4(1):60-70. PubMed ID: 5033956
    [No Abstract]   [Full Text] [Related]  

  • 26. [Phase III clinical study of a new anticancer drug atofluding].
    Li Q; Feng FY; Han J; Sui GJ; Zhu YG; Zhang Y; Zhang ZH; Li L; Wang PH; Zhou MZ; Zhang YC
    Ai Zheng; 2002 Dec; 21(12):1350-3. PubMed ID: 12520746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines.
    Pieńkowski T; Jagiello-Gruszfeld A
    Int J Clin Pharmacol Res; 2001; 21(3-4):111-7. PubMed ID: 12067140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of a combination of azotomycin (NSC-56654) and 5-fluorouracil (NSC-19893) in malignant disease.
    Weiss AJ; Mastrangelo MJ
    Cancer Chemother Rep; 1970 Apr; 54(2):109-11. PubMed ID: 4946000
    [No Abstract]   [Full Text] [Related]  

  • 29. Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer.
    Baker LH; Vaughn CB; al-Sarraf M; Reed ML; Vaitkevicius VK
    Cancer; 1974 Feb; 33(2):513-8. PubMed ID: 4812768
    [No Abstract]   [Full Text] [Related]  

  • 30. Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma.
    Dalley DN; Levi JA; Aroney RS
    Med J Aust; 1980 Mar; 1(5):216-8. PubMed ID: 6990214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phase II study of a new fluorinated pyrimidine, ethyl (+/-)-t-6-butoxy-5-fluoro-2, 4-dioxohexahydropyrimidine-r-5-carboxylate (TAC-278)].
    Gan To Kagaku Ryoho; 1982 Oct; 9(10):1821-6. PubMed ID: 7184376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe immune thrombocytopenia during formestane treatment.
    Español I; Muñíz-Díaz E; Alonso MC; Pujol-Moix N
    Haematologica; 1998 Oct; 83(10):953-4. PubMed ID: 9830809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Breast cancer].
    Wobbes T
    Ned Tijdschr Tandheelkd; 1992 Jan; 99(1):9-11. PubMed ID: 11819994
    [No Abstract]   [Full Text] [Related]  

  • 34. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
    Innocenti F; Ratain MJ
    Clin Cancer Res; 2002 May; 8(5):1314; author reply 1315-6. PubMed ID: 12006555
    [No Abstract]   [Full Text] [Related]  

  • 35. Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial.
    Tormey D; Gelman R; Falkson G
    Am J Clin Oncol; 1983 Feb; 6(1):1-18. PubMed ID: 6340458
    [No Abstract]   [Full Text] [Related]  

  • 36. [A clinical study of N-nitrosomethylurea].
    Vermel' EM; Korman NP; Milonov BV; Evseenko LS; Orlova RS
    Vopr Onkol; 1970 May; 16(5):31-7. PubMed ID: 4915916
    [No Abstract]   [Full Text] [Related]  

  • 37. Alkaline comet assay study with breast cancer patients: evaluation of baseline and chemotherapy-induced DNA damage in non-target cells.
    Kopjar N; Milas I; Garaj-Vrhovac V; Gamulin M
    Clin Exp Med; 2006 Dec; 6(4):177-90. PubMed ID: 17191110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
    Windschitl H; Scott M; Schutt A; McCormack G; Everson L; Cullinan S; Gerstner J; Krook J; Laurie J; Shreck R
    Cancer Treat Rep; 1983 Nov; 67(11):1001-8. PubMed ID: 6640551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Adjuvant therapy of breast cancer].
    Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
    Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
    [No Abstract]   [Full Text] [Related]  

  • 40. [Early phase II study of MST-16 (sobuzoxane) for breast cancer].
    Tominaga T; Shimozuma K; Hasegawa K; Hayashibara K; Nakahiro K; Nakao I; Katayama K; Fukuda M; Majima H; Aoyama H
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):1009-15. PubMed ID: 8210250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.